Seizert Capital Partners LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Seizert Capital Partners LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 45.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,014 shares of the biopharmaceutical company’s stock after selling 21,255 shares during the period. Seizert Capital Partners LLC’s holdings in Pfizer were worth $1,127,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Heritage Way Advisors LLC boosted its holdings in shares of Pfizer by 0.6% during the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock worth $2,492,000 after purchasing an additional 354 shares during the period. M Holdings Securities Inc. lifted its holdings in Pfizer by 27.9% in the first quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock worth $1,692,000 after buying an additional 8,693 shares during the period. Annex Advisory Services LLC lifted its holdings in Pfizer by 0.7% in the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock worth $2,243,000 after buying an additional 382 shares during the period. Princeton Global Asset Management LLC lifted its holdings in Pfizer by 14.7% in the first quarter. Princeton Global Asset Management LLC now owns 26,736 shares of the biopharmaceutical company’s stock worth $1,135,000 after buying an additional 3,429 shares during the period. Finally, GYL Financial Synergies LLC lifted its holdings in Pfizer by 105.3% in the first quarter. GYL Financial Synergies LLC now owns 22,987 shares of the biopharmaceutical company’s stock worth $976,000 after buying an additional 11,788 shares during the period. Institutional investors own 71.58% of the company’s stock.

Several brokerages have commented on PFE. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. UBS Group restated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Morgan Stanley lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $48.00 to $40.00 in a report on Tuesday, July 30th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $49.00 price objective on shares of Pfizer in a report on Monday, June 17th. Fourteen analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $46.67.

Shares of NYSE PFE traded down $0.74 on Friday, reaching $34.34. 20,323,181 shares of the company’s stock traded hands, compared to its average volume of 35,302,192. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The business’s 50 day simple moving average is $39.60 and its two-hundred day simple moving average is $41.43. The company has a market cap of $194.03 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.80 and a beta of 0.63. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s dividend payout ratio is 48.00%.

In related news, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares of the company’s stock, valued at $3,524,136. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Trade War

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.